Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives

Disease-modifying therapies (DMTs) have significantly advanced the treatment of relapsing multiple sclerosis (MS), decreasing the frequency of relapses, disability, and magnetic resonance imaging lesion formation. However, patients' responses to and tolerability of DMTs vary considerably, creat...

Descripción completa

Detalles Bibliográficos
Autor principal: Coyle, Patricia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540248/
https://www.ncbi.nlm.nih.gov/pubmed/28804651
http://dx.doi.org/10.1155/2017/6198530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540248/
https://www.ncbi.nlm.nih.gov/pubmed/28804651
http://dx.doi.org/10.1155/2017/6198530

Ejemplares similares